President’s Letter: I’m proud to start out this newsletter by letting you know that TransPharm Preclinical Solutions has once again received recommendation for accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International. AAALAC accreditation is evaluated every three years, with our recent site visit on July 20th. Programs constantly change, along with the regulations in the use of animals in research. AAALAC’s mission is to ensure that all of these changes are in force and the Program Description for our facility is accurate, complete and adhered to. The continued success of our program is directly related to those individuals on our Institutional Animal Care and Use Committee, or IACUC. I would like to personally thank all those individuals. Libby Ziemke, IACUC administrator Marci Peek, Chair Dr. Megan Nowland, attending Veterinarian and Alternate Chair Joanne Zammit, Scientist Dr. Santiago Lopez, Scientist Dan Wymer, Non-Scientist Dr. Jim Mobley, Alternate scientist Adhering to these global standards is what lead to our success three years ago. This continued recommendation for accreditation bodes well for our continued success. To learn more about AAALAC International please visit: www.aaalac.org Towards our commitment for high quality research, four individuals here at TransPharm have recently taken their respective level of certification through the American Association of Laboratory Animal Science. AALAS offers these nationwide board exams after certain criteria is met by the individual taking the exam. I would like to congratulate: Heidi Richardson, ALAT level Marci Peek, LAT level Libby Ziemke, LATG level Lisa Lazaroff, LATG level To learn more about AALAS please visit www.aalas.org Dan Clostridium difficile murine model In an effort to provide our clients with the most robust and effective murine models of infection, TransPharm has adopted a new bacterial spore preparation for our C. difficile-associated disease model. This improved protocol has been thoroughly validated and rigorously compared to our previous procedure. It has surpassed TransPharm’s high standard of scientific excellence (Figures 1-3), much to the satisfaction of our valued clients with whom we’ve had the pleasure of collaborating. So, if your group is in the market for a murine model of C. difficile-associated disease (or any other infectious disease model), there’s no better time to talk with us! Don’t forget...Read More
TransPharm has given me some wonderful opportunities over the last 4 years. Locally, we volunteer for Junior Achievement, Big Brothers/Big Sisters, and donate to numerous charities that I wouldn’t have been able to do in the past.
At the state level, we were awarded as one of the Top 50 Companies to Watch in Michigan in 2011. I was invited to a business round table discussion and met with Jennifer Granholm, Michigan’s outgoing Governor. In the last two months, I was invited to Governor Rick Snyder’s residence in Lansing for the Moores River Drive Breakfast. Both events brought together many of the States business leaders and gave us a chance to meet with many of our States representatives and hear some of the new initiatives that are in the works for small business owners.Read More
President’s Letter: Let me be the last person to wish you a Happy New Year! 2011 proved to be a year full of challenges and rewards for us here at TransPharm. We have had many requests to run in vivo models of pathogens we have not yet validated. While it’s nearly impossible to have data in hand for all the possible requests we could see, we are now fully committed to putting more resources into new project validations. TransPharm has many new models that we plan to roll out in 2012 and Dr. Lopez will touch on a few of those below. Marci Peek, our Contract & Protocol Specialist, will also inform you of some news regarding our product, the Final Report. We closed the year with a 15% increase in revenue over 2010, making it our best year to date. This is one reason TransPharm will be making new commitments to our clients in 2012. Our pricing structure will remain untouched, new models will be rolled out and our new Final Report Guarantee are just a few ways we are saying thank you for your business. Dan TransPharm is going viral! The year 2012 promises many exciting projects for the Research and Development team here at TransPharm! One of these projects involves the expansion of our current models of infection to now include viral models, namely Herpes Simplex Virus (HSV) types 1 and 2. With the various clinical manifestations of this pathogen and its worldwide spread, we believe HSV is a logical entry point into the viral infection modeling realm. TransPharm is currently in the process of developing and validating both an in vitro model to detect early viral mRNA transcripts as well as an in vivo sepsis model of HSV infection. We have also laid the groundwork to explore the murine model of latency and reactivation of all herpes viruses. Another area of research we are excited about is the development of a mouse model for malaria infections (Plasmodium falciparum). Being the world’s second biggest killer (just behind tuberculosis) and with relatively little research going into anti-malaria medications, TransPharm believes this model will aid in the search for cost-effective treatments for this deadly disease. So stay tuned...Read More
TransPharm Preclinical Solutions in Napoleon Township has been recognized as one of 2011’s “Michigan 50 Companies to Watch” by the Cassopolis-based Edward Lowe Foundation. TransPharm will be honored at an award ceremony during the seventh annual Michigan Celebrates Small Business event April 28 in Lansing. President and CEO Dan Ross said the award is a great accomplishment for his company. Read...Read More
Dan Ross is another example of the pharmaceutical industry’s cutbacks spawning Michigan entrepreneurship — and another example of how the Michigan Small Business and Technology Development Center helps companies grow. Ross, trained as a veterinary technician was a surgical technician at Wayne State University and later an associate scientist at Parke-Davis in Ann Arbor, staying through its transition to Pfizer Inc. ownership. But when Pfizer announced in 2007 it was shutting down its Ann Arbor research operations, Ross was already thinking about striking out on his own. Read...Read More